OneMedNet Corp (ONMD): Depreciation & Amortization
$65.0K
Year ended 2025-12-31
+37.5%
3-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $65.0K | +14.0% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $57.0K | +103.6% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $28.0K | +12.0% | 2025-04-15, From 2023-01-01 |
| 2022-12-31 | $25.0K | n/a | 2024-11-05, From 2022-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| OneMedNet Corp (ONMD) | 2025-12-31 | $65.0K | +14.0% |
| iSpecimen Inc. (ISPC) | 2025-12-31 | $1.73M | -24.6% |
| Absci Corp (ABSI) | 2025-12-31 | $11.74M | -12.3% |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | $504.8K | -16.6% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $597.4K | -51.6% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $21.75M | -7.8% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $4.34M | +0.6% |
| NRC Health (NRC) | 2025-12-31 | $7.62M | +26.6% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $403.31M | +11.5% |
Compare ONMD, ISPC, ABSI, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗